Alligator Bioscience presents new preclinical results for the bispecific antibody ATOR-4066 at the 9th International Conference on Cancer Immunotherapy (CICON25) in Utrecht. ATOR-4066 is designed to activate the immune system against CEACAM5-positive cancers. Data show that the antibody potently stimulates both myeloid cells and T cells in the tumor, eliminates established tumors, and exhibits enhanced efficacy when combined with PD-1 blockade.
|
Published September 12, 2025
Alligator presents preclinical data for ATOR-4066
Notes
Johnson & Johnson acquires Halda Therapeutics for $3 billion
Magle Group submits application for EmboCept S
Quia Pharma is delisted from Nasdaq
Stenocare acquires CannGros
Lundbeck enters the fight for Avadel
Klaria's partner CNX starts production of migraine film
Sofinnova Partners raises EUR 650 million in new fund
NEWSLETTER
Today's news roundup
News roundup Monday, November 17
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Pila Pharma stands out in next-generation obesity pipeline
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
SwedenBIO wants to give growth power to the industry
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account